Veraxa Biotech AG (VRXA) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Veraxa Biotech AG (VRXA) closed at USD 1.11 on 2026-10-14, a change of -89.4 % over the past year, with a market capitalization of USD 155.55M.
Veraxa Biotech AG recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.11 |
| 2026-10-13 | 1.20 |
| 2026-10-12 | 1.14 |
| 2026-10-09 | 1.26 |
| 2026-10-08 | 1.09 |
| 2026-10-07 | 1.20 |
| 2026-10-06 | 1.08 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Veraxa Biotech AG key figures
- Previous close
- USD 1.11 (2026-10-14)
- 1-year change
- -89.4 %
- Market cap
- USD 155.55M
- Enterprise value
- n/a
- P/E ratio (trailing)
- -2.12
- P/E ratio (forward)
- n/a
- EPS (trailing)
- -0.52
- EPS (forward)
- n/a
- PEG ratio
- n/a
- Price to book
- -0.86
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.76
- Employees
- n/a
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Veraxa Biotech AG
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Veraxa Biotech AG and compare it with other stocks.
Analyze VRXAAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Veraxa Biotech AG shares.